Lytus Technologies PTV. .-PureTech Presents New Data from Phase 2b Open-Label Extension Study of Deupirfenidone (LYT-100), Further Supporting Strong and Durable Efficacy and Potential to Serve as New Standard of Care in IPF

PureTech Presents New Data from Phase 2b Open-Label Extension Study of Deupirfenidone (LYT-100), Further Supporting Strong and Durable Efficacy and Potential to Serve as New Standard of Care in IPF

Lytus Technologies PTV. .(US:LYT) Businesswire·2025-09-29 14:00

核心观点 - PureTech公司公布了Deupirfenidone治疗特发性肺纤维化（IPF）的2b期开放标签扩展研究新数据这些数据进一步支持该药物有潜力成为IPF的新标准疗法 [1] 临床数据进展 - 新数据来自Deupirfenidone的2b期开放标签扩展研究 [1] 产品潜力与定位 - Deupirfenidone有潜力成为IPF的新标准疗法 [1]